|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
L Capital Invests $2 Million in iScience Interventional
April 21st, 2009 No comments
Breakthrough Treatment for Glaucoma
NEW YORK L Capital Partners, L.P., a venture capital firm in New York City, is investing $2 million in a $20 million Series F round of financing for iScience Interventional. The round is being led by Affinity Venture Group; other investors include Johnson & Johnson Development Corporation, Clarian Health Ventures and existing investors. Ting Pau Oei, L Capital partner, will join the iScience Board of Directors.
iScience Interventional has developed a revolutionary new microcatheter that allows, for the first time, site-specific treatments for glaucoma, a disease that affects 8.6 million people every year. The device has been cleared by the FDA and is used in a procedure called canaloplasty that stops the progression of the disease which can cause loss of sight.
iScience Interventional is a medical device company dedicated to developing the smallest microcatheters in medicine and novel microcatheter-based procedures for the eye. iScience has developed a microcatheter that is so thin it can access small, sensitive spaces within the eye. Its size is essentially equal to putting together 4 or 5 strands of hair. Glaucoma specialists & ophthalmologists are excited because this device allows them, for the first time, to navigate the anatomical structure of the eye without causing tissue damage.
Canaloplasty is a proprietary procedure and is the first and only microcatheter-based method to treat glaucoma. It is like angioplasty for the eye. The microcatheter’s illuminated beacon tip provides the doctor with exceptional visibility and trackability. Canaloplasty restores the natural drainage of the eye resulting in a significant reduction in intraocular pressure, thus preventing the disease from progressing.
Until now, traditional glaucoma treatments relied primarily on pharmaceutical regimens and/or more invasive surgical procedures. Canaloplasty reduces the dependence on medication in glaucoma patients.
Ting Pau Oei is a partner at L Capital Partners and leads the investments in the health care sector. Mr. Oei said: “The field of ophthalmology has been of great interest to L Capital for several years. iScience represents an opportunity to invest in a company with a unique technology targeting an underserved population: people suffering from glaucoma. iScience provides ophthalmologists and patients with a novel treatment. L Capital sees this as a terrific growth opportunity that fits in with our investment strategy of helping to bring breakthrough technologies to market.”
Mike Nash is a co-founder of iScience and President and CEO. Nash said: “ I am very excited to have Ting Pau Oei’s involvement on the Board because he understands how the scientific, clinical and strategic opportunities work together. The additional funding will enable iScience to build upon its unique position in the marketplace, continue commercial activities for glaucoma and develop further applications for treatments in the eye.”
About iScience Interventional
iScience Interventional is committed to creating breakthrough technologies for sight-threatening diseases. iScience not only researches and develops new approaches for addressing eye diseases, but also facilitates access through training and comprehensive support materials to help opthamologists successfully utilize these innovative techniques. The company is based in Menlo Park, California. For more information, visit www.iscienceinterventional.com.
About L Capital Partners
L Capital Partners invests in development and later-stage companies in the healthcare, technology and energy & environment sectors. To help their portfolio companies realize the promise of transformational change, L Capital Partners is a committed multi-round investor that supports each company with a team of partners, principals and associates who have deep industry and financial expertise. In the healthcare sector, the firm targets companies in the areas of biopharmaceuticals and medical devices. Established in 2004, L Capital Partners has offices in New York and Tel Aviv. For more information, visit www.lcapitalpartners.com.
Source: L Capital Partners, L.P.
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility